Smith & Nephew PLC header image

Smith & Nephew PLC

SNN

Equity

ISIN null / Valor 1111046

CTA NASDAQ OMX Stock Exchange (2026-05-01)
USD 31.16+0.74%

Smith & Nephew PLC
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Smith & Nephew PLC is a global medical technology company that develops and manufactures a wide range of clinical devices and solutions for orthopaedics, advanced wound management, sports medicine, and ear, nose, and throat (ENT) procedures. The company’s orthopaedics division produces implants for hip and knee joint replacements, along with trauma products designed to stabilize fractures and correct bone deformities, while also incorporating robotics-assisted technologies to support surgical precision. Its advanced wound management offerings cover a variety of products for treating both acute and chronic wounds, including conditions such as diabetic and pressure ulcers, burns, and post-operative complications. In addition, the sports medicine and ENT portfolios provide instruments and implants for minimally invasive soft tissue repairs and various ENT procedures. Overall, Smith & Nephew leverages these diversified capabilities to address a broad spectrum of clinical needs within the healthcare sector.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

10.4%1Y
-4.62%3Y
-27.8%5Y

Performance

28.7%1Y
64.9%3Y
53.1%5Y

Volatility

Market cap

13239 M

Market cap (USD)

Daily traded volume (Shares)

1,391,587

Daily traded volume (Shares)

1 day high/low

24.76 / 24.55

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc Amphastar Pharmaceuticals Inc Valor: 24511852
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.36%USD 21.88
Schrodinger Inc
Schrodinger Inc Schrodinger Inc Valor: 51947209
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.60%USD 12.39
International Flavors & Fragrances Inc
International Flavors & Fragrances Inc International Flavors & Fragrances Inc Valor: 941876
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.87%USD 70.81
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.35%USD 2.84
Outset Medical Inc
Outset Medical Inc Outset Medical Inc Valor: 56717137
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.11%USD 4.36
BridgeBio Pharma Inc
BridgeBio Pharma Inc BridgeBio Pharma Inc Valor: 48204826
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.59%USD 68.56
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc Protagonist Therapeutics Inc Valor: 33278818
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.61%USD 98.37
Allogene Therapeutics Inc
Allogene Therapeutics Inc Allogene Therapeutics Inc Valor: 43756548
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.94%USD 2.15
Summit Therapeutics Inc
Summit Therapeutics Inc Summit Therapeutics Inc Valor: 56903013
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-24.91%USD 16.11
Glaukos Corp
Glaukos Corp Glaukos Corp Valor: 28262610
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.40%USD 140.22